Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG301 Injection in Patients With Antibody-Mediated Rejection (AMR) After Renal Transplantation

NCT07764627 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.

NCT NCT07764627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG301 Injection in Patients With Antibody-Mediated Rejection (AMR) After Renal Transplantation
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 30, 2028
Enrollment
10 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

antibody mediated rejection